Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: A-HYDROCORT

« Back to Dashboard
A-hydrocort is a drug marketed by Abbott and Hospira and is included in ten NDAs.

The generic ingredient in A-HYDROCORT is hydrocortisone sodium succinate. There are fifty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocortisone sodium succinate profile page.

Summary for Tradename: A-HYDROCORT


Clinical Trials for: A-HYDROCORT

The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism
Status: Recruiting Condition: Hypopituitarism; Hydrocortisone; Lipids; Fatty Acids, Nonesterified; Insulin Sensitivity

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
Status: Recruiting Condition: Addison Disease; Adrenal Hyperplasia Congenital

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Status: Completed Condition: Congenital Adrenal Hyperplasia; 21-Hydroxylase Deficiency; Adrenogenital Syndrome

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Status: Completed Condition: Adrenal Insufficiency

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Status: Completed Condition: Major Depressive Disorder; Anxiety Disorders

Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only
Status: Completed Condition: Healthy

Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency
Status: Completed Condition: Primary Adrenal Insufficiency

Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
Status: Enrolling by invitation Condition: Adrenal Insufficiency

An Investigational Study of Hydrocortisone
Status: Completed Condition: Adrenal Insufficiency

Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia
Status: Completed Condition: Fibromyalgia

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
hydrocortisone sodium succinate
INJECTABLE;INJECTION089580-001Apr 11, 1989DISCNNo<disabled><disabled>
hydrocortisone sodium succinate
INJECTABLE;INJECTION040666-001Apr 6, 2006RXNo<disabled><disabled>
hydrocortisone sodium succinate
INJECTABLE;INJECTION089578-001Apr 11, 1989DISCNNo<disabled><disabled>
hydrocortisone sodium succinate
INJECTABLE;INJECTION085929-001Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
hydrocortisone sodium succinate
INJECTABLE;INJECTION085928-001Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn